

EER001032	Duplica <sup>Real time</sup> Factor II G20210A Genotyping Kit	32 tests
EER002032	Duplica <sup>Real time</sup> Factor V G1691A Genotyping Kit	32 tests
EER003032	Duplica <sup>Real time</sup> MTHFR C677T Genotyping Kit	32 tests
EER004032	Duplica <sup>Real time</sup> Haemochromatosis Genotyping Kit	32 tests
EER005032	Duplica <sup>Real time</sup> Haemochromatosis C282Y Kit	32 tests
EER006032	Duplica <sup>Real time</sup> Haemochromatosis H63D Kit	32 tests
EER007032	Duplica <sup>Real time</sup> MTHFR A1298C Genotyping Kit	32 tests
EER010032	Duplica <sup>Real time</sup> Factor V 1299 Genotyping Kit	32 tests
EER013032	Duplica <sup>Real time</sup> Factor V Y1702C Genotyping Kit	32 tests



Duplica<sup>Real Time</sup> Kits

# Allelic Discrimination in cardiovascular diseases

"THE PURCHASE OF THIS PRODUCT GRANTS THE PURCHASER RIGHTS UNDER CERTAIN ROCHE PATENTS TO USE IT SOLELY FOR PROVIDING HUMAN IN VITRO DIAGNOSTIC SERVICES. NO GENERAL PATENT OR OTHER LICENSE OF ANY KIND OTHER THAN THIS SPECIFIC RIGHT OF USE FROM PURCHASE IS GRANTED HEREBY"

All products included in this leaflet are licensed by Roche.



EUROCLONE S.p.A.  
Life Sciences Division, Via Lombardia, 12  
27010 Sizzano (PV) Italy  
Tel. +39.02.38195378-Fax +39.02.38195230  
E-mail: info@euroclone.net

Local Distributor

ed2/0706/272

[www.euroclone.net](http://www.euroclone.net)



**EuroClone**<sup>®</sup>

## COAGULATION DISORDERS IN A WIDE RANGE OF PATHOLOGIES THROUGH A MULTIFACTORIAL GENETIC ANALYSIS

Venous thromboembolism (VTE) is a widespread health problem that causes significant morbidity and mortality (1,2). In pathogenetic respects, the condition appears to be of pleiotropic origin, involving both intrinsic (genetic predispositions) and environmental (e.g., oral contraceptives and smoking) factors (1).

Generally accepted or "classically" acquired risk factors for venous thromboembolism include advanced age, prolonged immobilisation, surgery, fractures, use of oral contraceptives and hormone replacement therapy, pregnancy, puerperium, cancer and antiphospholipid syndrome.

Morover, in recent years, due to the high doses of hormones intake in women undergoing IVF (In Vitro Fertilization), the genetic analysis of mutations linked to thrombotic disease seems to be more and more frequent in many labs. Mutations in coagulation factor genes (Prothrombin G20210A and Factor V Leiden) may cause thrombotic complications in ovarian hyperstimulation syndrome (OHSS) and screening for this abnormality in women undergoing IVF may be indicated (3).

The presence of thrombogenic mutations (Prothrombin G20210A, Factor V Leiden, MTHFR C677T) has been found in a significant number of cases of obstetric complications attributable to placental thrombosis and they might be related to infertility and recurrent spontaneous abortion (RSA) also(4,5), oral contraception (6,7) and postmenopausal therapy (8)

The Euroclone concept genetic trombophilia diagnosis is the **multifactor analysis of genetic polymorphisms**. The most common mutations (Factor V Leiden, Factor II and MTHFR) are now rounded off (implemented) by the investigation of new parameters (Factor V 1299, Factor V Y1702C etc) that strengthen the diagnostic sense of this approach.

### References

- (1) Rees, D.C., Cox, M., and Clegg, J.B. (1995) World distribution of factor V Leiden. *Lancet* 346:1133-1134.
- (2) Dzimir, N. and Meyer, B. (1996) World distribution of factor V Leiden. *Lancet* 347:481-482.
- (3) Ellis MH et al «Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome.» *Fertil Steril.* 1998 Jan;69(1):140-2.
- (4) Bare SN et al. «Factor V Leiden as a risk factor for miscarriage and reduced fertility.» *Aust N Z J Obstet Gynaecol.* 2000 May;40(2):118-21.
- (5) Behjati et al «Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion» *Ann Hematol.* 2006 Apr;85(4):268-71.
- (6) Mohllajee et al «Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review.» *Contraception.* 2006 Feb;73(2):166-78.
- (7) Aznar J. et al «Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.» *Haematologica.* 2000 Dec;85(12):1271-6.
- (8) Straczek et al.«Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.» *Circulation.* 2005 Nov 29;112(22):3495-500.

## Duplica<sup>Real Time</sup> Kits, the easiest way for your Real Time protocol

<b>EASY:</b>	Ready-to-use reagents
<b>FLEXIBLE:</b>	Single Protocol suitable for multiple applications
<b>FAST:</b>	Amplification and Detection in a single reaction
<b>AUTOMATIC:</b>	Genotyping through analysis software
<b>RELIABLE:</b>	Protocol Standardization
<b>SAFE:</b>	No cross-reaction for post-PCR manipulations
<b>MULTIPARAMETRIC:</b>	A new and complete diagnosis system


**Real Time PCR technology** allows the DNA target to be simultaneously amplified and detected.

Duplica<sup>Real Time</sup> allelic discrimination kits, are provided with two ready-to-use reaction mixes (Amplification Mix and Oligo Mix).

The Amplification Mix contains Hot Start Taq DNA polymerase, nucleotides, MgCl<sub>2</sub>, buffer.

The Oligo Mix contains primers and fluorogenic probes specific for Wild Type(WT) and Mutated (Mut) alleles.

The kits are compatible with most Real Time platforms.



READY, STEADY, GO PROTOCOL